These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 20126991

  • 1. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
    Pasquini L, Petronelli A, Petrucci E, Saulle E, Mariani G, Scambia G, Benedetti-Panici P, Greggi S, Cognetti F, Testa U.
    Int J Oncol; 2010 Mar; 36(3):707-13. PubMed ID: 20126991
    [Abstract] [Full Text] [Related]

  • 2. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U.
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [Abstract] [Full Text] [Related]

  • 3. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [Abstract] [Full Text] [Related]

  • 4. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [Abstract] [Full Text] [Related]

  • 5. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [Abstract] [Full Text] [Related]

  • 7. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.
    J Natl Cancer Inst; 2008 May 07; 100(9):649-62. PubMed ID: 18445820
    [Abstract] [Full Text] [Related]

  • 8. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A.
    Clin Cancer Res; 2005 Jun 01; 11(11):4259-65. PubMed ID: 15930365
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
    Brüning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, Burges A.
    Invest New Drugs; 2009 Dec 01; 27(6):543-51. PubMed ID: 19039521
    [Abstract] [Full Text] [Related]

  • 10. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
    Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R.
    J Clin Endocrinol Metab; 2007 May 01; 92(5):1938-42. PubMed ID: 17327374
    [Abstract] [Full Text] [Related]

  • 11. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
    Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN.
    Oncotarget; 2014 Aug 30; 5(16):7065-80. PubMed ID: 25216523
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
    Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, Goldstein RS, Roitman V, Slavin S, Mikkelsen T, Brodie C.
    Cell Signal; 2011 Aug 30; 23(8):1348-57. PubMed ID: 21440622
    [Abstract] [Full Text] [Related]

  • 13. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 15. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
    Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J, Walczak H.
    Oncogene; 2015 Apr 16; 34(16):2138-2144. PubMed ID: 24909167
    [Abstract] [Full Text] [Related]

  • 16. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW.
    Biochem Biophys Res Commun; 2011 Dec 09; 416(1-2):222-5. PubMed ID: 22120628
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 Jun 15; 17(12):4019-30. PubMed ID: 21525171
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

  • 19. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
    Laussmann MA, Passante E, Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M.
    J Biol Chem; 2012 Apr 27; 287(18):14402-11. PubMed ID: 22408249
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
    Koschny R, Boehm C, Sprick MR, Haas TL, Holland H, Xu LX, Krupp W, Mueller WC, Bauer M, Koschny T, Keller M, Sinn P, Meixensberger J, Walczak H, Ganten TM.
    J Neuropathol Exp Neurol; 2014 Nov 27; 73(11):1034-46. PubMed ID: 25289891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.